Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why GNBT has an Advantage in the Covid-19 Vaccine Race Rapid Path to SARS-COV-2 Vaccine: 3 Months to Human Vaccination
NuGenerex Immuno-Oncology, a Subsidiary of Generex Biotechnology (NGIO) has developed our proprietary, patented Ii-Key immune system
activation technology that holds promise for stopping pandemic viral outbreaks like the current SARS-COV-2 coronavirus epidemic in China. NGIO has invested over $50 million in the last 15 years to develop the Ii-Key technology for infectious disease & cancer immunotherapy. The
focus of NGIO is on cancer immunotherapy, the company previously maintained a robust research and development effort for potentially pandemic viruses avian flu (H5N1),swine flu (H1N1) and SARS, creating on-demand peptide vaccines that have been extensively studied through human clinical trials NGIO’s Ii-Key antigenic peptides have been shown to supercharge the immune system up to 100 times more than peptides alone. The activity and safety of Ii Key peptide vaccines has been proven in Phase I and II clinical trials involving over 300 patients or volunteers, so new Ii-Key has been proven in Phase I
and II clinical trials involving over 300 patients or volunteers, so new Ii-Key vaccines should be able to proceed directly to human studies without significant pre-clinical toxicology testing. With human clinical data in hundreds of patients that demonstrate safety and immune system activation against infectious disease and tumor antigens, as well as preclinical in vitro and in vivo studies that prove the mechanism of T-Cell activation, the Ii-Key technology offers a rapid path to humanprotection from the SARS-COV-2 and COVID-19 epidemic.
NGIO is working with EpiVax to utilize their proprietary computational vaccinology algorithms and databases to guide the rapid development of Ii-Key peptide vaccines to protect against the spread of SARS-COV-2. EpiVax has developed a suite of online computational vaccinology tools
for the accelerated design of proteome-derived, epitope-driven vaccines. NGIO and EpiVax are generating new patents and intellectual
properties from this collaborative agreement.
https://www.techtimes.com/articles/248421/20200328/covid-19-patients-show-sign-progress-after-taking-in-development-hiv-and-breast-cancer-drug-now-free-from-ventilators.htm
https://techstartups.com/2020/03/27/coronavirus-cure-new-results-french-study-shows-combination-hydroxychloroquine-plaquenil-azithromycin-successfully-treated-80-coronavirus-patients-significant-dr/
https://www.theguardian.com/world/2020/mar/28/coronavirus-cure-fact-check-hydroxychloroquine-trump
Last week, under FDA approval, the drug leronlimab was tested in patients with serious respiratory conditions with Covid-19 in NY
https://seekingalpha.com/article/4334730-cytodyn-may-be-one-of-first-biotechs-to-drug-helps-against-covidminus-19
The respiratory condition that is so dangerous in Covid-19 results from a condition called a "cytokine storm." CytoDyn (OTCQB:CYDY) believes that filling the CCR5 receptor with a harmless monoclonal body will prevent further damage.
Authors Comment
Thomas Barnard
Comments174 | + Follow
Author’s reply »
Leronlimab may be useful for extreme cases with the cytokine storms, but many of us older folks are hoping that companies like Generex (GNBT) will stay the course because the epidemiologists say this disease is now out in the general population from here forward. Generex's Ii-key technology may be one of the best for vaccine development, which could save us from catching one of these horrible cases.
https://seekingalpha.com/article/4334730-cytodyn-may-be-one-of-first-biotechs-to-drug-helps-against-covidminus-19
Authors Comment
Thomas Barnard
Comments174 | + Follow
Author’s reply »
Leronlimab may be useful for extreme cases with the cytokine storms, but many of us older folks are hoping that companies like Generex (GNBT) will stay the course because the epidemiologists say this disease is now out in the general population from here forward. Generex's Ii-key technology may be one of the best for vaccine development, which could save us from catching one of these horrible cases.
Authors Comment
Thomas Barnard
Comments174 | + Follow
Author’s reply »
Leronlimab may be useful for extreme cases with the cytokine storms, but many of us older folks are hoping that companies like Generex (GNBT) will stay the course because the epidemiologists say this disease is now out in the general population from here forward. Generex's Ii-key technology may be one of the best for vaccine development, which could save us from catching one of these horrible cases.
https://seekingalpha.com/article/4334730-cytodyn-may-be-one-of-first-biotechs-to-drug-helps-against-covidminus-19
If successful many newbies will come here in masses. Info is ready for the DD crowd.
Headline: COVID-19:Generex/Epivax Vaccine Chinese Funded Trials Within 90 Days
World Health Org Listing: Generex-EpiVax/Li Key Peptide Vaccine/PDF File Pg 3!!
|Generex GNBT Wall Street Journal |OTC-QB GNBT|Generex GNBT Globe News Wire|
|China Companies Contract Generex for Covid -19 Vaccine You Tube Media Link|
Top of the box with links
Repeat: India and the world are on LOCKDOWN.
Interesting post. Progress being made.
India is locked down, giving it till 2021
Willians and Hartigan decided to join a sinking ship. yeah right
Dividend Stocks are cheap Hint.
REITS are cheap Hint..
I-Box update
Waiting game is on. A Covid-19 Vaccine that works or helps people that fall ill with respiratory failure would be great!!
Be careful and stay clear of large crowds.
doc, the Covid-19 is the problem "excuse", things get pushed back, Until we see the extent of Covid and a Vaccine we don't know. Everything has changed drastically in case you have not noticed. They also said in January royalties will start in 2021.
What 1M? for the reactors. is questioning everything ok, maybe if your short or work for K&L Gates. India is on hold so is the globe. Might as well chuck 2020 on the QTMM Im on hold waiting for 2021 and getting a handle on the Virus.
The QD Blockchain and Displays are still in the picture.
Insider Buys in the 5's PE under 3. This sector will recover (stock wise) once Covid-19 is under control and a moderately good sector of the REITS all on sale. Overweight if you have year + horizon. Oversold.
Patience pays.
January '20 letter of intent signed for $2M equity investment and Joint Venture to form Quantum Materials Vertical Technologies, LLC.
Shakers are after cheap shares
Great Idea, just in case Generex has the vaccine this will explode upwards. Their odds are excellent.
Scotty beamed me over to India. along with an 8K. Remember question everything including Covid-19.
Hartigan said they have sales. I believe him over the board.
Im still holding QTMM and purchased some yesterday oh BTW.
QMC's Reactors are sitting in India waiting for the Corona crap to settle down. 1 of The othre companies I am Invested in is being Funded by China for a Vaccine and on the WHO Website.
I trimmed back a month ago. and buying REITS. Hell QTMM can go to .000001 with little effect.
I work in the Medical Field Gown Glove Mask aand not bring it home to my wife. What Covid Breakout. ?????
The rest of my portfolio is cushioning QTMM, when Tech City gets going in 2021 or possibly sooner. I think long term.
January '20 letter of intent signed for $2M equity investment and Joint Venture to form Quantum Materials Vertical Technologies, LLC.
Great article, thanks yes the potential in this area is vast.
WHO Listed Covid-19 Protein Subunit Vaccine PG 2 PDF & Video
https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1
For every sell there is a buyer. People look at their portfolio and see a couple of million shares and maybe unload a few so they can buy an undervalued REIT. No big deal fortunately there are people who are also adding. The person who bought the the .0038 congrats. Im with the board that MILV will be successful.
DC Bound per FB & "other" comments. Speculating a bit may have to do with the Covid 19 China FDA and DJT? We'll see.
Future Bright & OTC Disclosures
Public service, give me a break. So the QD's don't work ask Nanosys and Samsung that.
I believe Steve sorry.